MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
DENTSPLY SIRONA General and Administrative Expenses 2011-2026 | XRAY
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses DENTSPLY SIRONA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.44 B | 1.6 B | 1.61 B | 1.59 B | 1.55 B | 1.3 B | 1.59 B | 1.72 B | 1.67 B | 1.52 B | 1.08 B | 1.14 B | 1.14 B | 1.15 B | 937 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.72 B | 937 M | 1.4 B |
Quarterly General and Administrative Expenses DENTSPLY SIRONA
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 351 M | - | 355 M | 342 M | 358 M | - | 390 M | 399 M | 415 M | - | 372 M | 416 M | 416 M | - | 401 M | 410 M | 376 M | - | 395 M | 393 M | 386 M | - | 315 M | 261 M | 359 M | - | 399 M | 431 M | 432 M | - | 418 M | 432 M | 435 M | - | 430 M | 418 M | 405 M | - | 379 M | 402 M | 342 M | - | 264 M | 275 M | 270 M | - | 276 M | 296 M | 288 M | - | 269 M | 290 M | 294 M | - | 260 M | 296 M | 304 M | - | 231 M | 211 M | 201 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 435 M | 201 M | 349 M |
General and Administrative Expenses of other stocks in the Medical instruments industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
23.2 K | - | - | $ 810 M |  USA |
 |
The Cooper Companies
COO
|
1.63 B | $ 67.16 | 8.29 % | $ 13.4 B | USA |
 |
Glaukos Corporation
GKOS
|
332 M | $ 125.17 | 2.86 % | $ 7.16 B | USA |
 |
Luminex Corporation
LMNX
|
140 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
3.73 M | - | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
251 M | $ 66.75 | 0.26 % | $ 40.4 B |  Schweiz |
 |
Intuitive Surgical
ISRG
|
2.38 B | $ 424.54 | 1.37 % | $ 152 B | USA |
 |
ICU Medical
ICUI
|
625 M | $ 136.91 | 1.47 % | $ 3.37 B | USA |
 |
iRhythm Technologies
IRTC
|
493 M | $ 106.88 | -0.44 % | $ 3.42 B | USA |
 |
Repro Med Systems
KRMD
|
23.4 M | $ 4.0 | -3.38 % | $ 185 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
62.8 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
198 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
8.44 M | - | - | $ 282 M | USA |
 |
LeMaitre Vascular
LMAT
|
42 M | $ 94.78 | 1.3 % | $ 2.15 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
941 M | - | -0.05 % | $ 10.3 B | USA |
 |
Masimo Corporation
MASI
|
744 M | $ 178.9 | - | $ 9.54 B | USA |
 |
Microbot Medical
MBOT
|
8.46 M | $ 1.84 | -6.12 % | $ 84.3 M |  Israel |
 |
Ekso Bionics Holdings
EKSO
|
9.99 M | - | - | $ 28.6 M | USA |
 |
Milestone Scientific
MLSS
|
11.6 M | $ 0.4 | -8.16 % | $ 32.8 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
671 M | - | -0.02 % | $ 16.3 B | USA |
 |
electroCore
ECOR
|
38.2 M | $ 8.81 | -11.37 % | $ 74.7 K | USA |
 |
Envista Holdings Corporation
NVST
|
1.16 B | $ 23.04 | 0.72 % | $ 3.87 B | USA |
 |
Haemonetics Corporation
HAE
|
442 M | $ 71.32 | 2.1 % | $ 3.36 B | USA |
 |
Isoray
ISR
|
30.2 M | - | 0.03 % | $ 108 M | USA |
 |
STERIS plc
STE
|
1.41 B | $ 213.18 | 0.44 % | $ 20.9 B | USA |
 |
STAAR Surgical Company
STAA
|
85.8 M | $ 29.69 | -0.57 % | $ 1.47 B | USA |
 |
InfuSystem Holdings
INFU
|
57 M | $ 9.3 | 1.97 % | $ 192 M | USA |
 |
Teleflex Incorporated
TFX
|
720 M | $ 131.5 | -0.46 % | $ 5.87 B | USA |
 |
Utah Medical Products
UTMD
|
7.88 M | $ 68.72 | 1.08 % | $ 223 M | USA |
 |
Merit Medical Systems
MMSI
|
455 M | $ 64.14 | 1.74 % | $ 3.79 B | USA |
 |
West Pharmaceutical Services
WST
|
394 M | $ 317.2 | -0.04 % | $ 22.9 B | USA |
 |
Pulse Biosciences
PLSE
|
32 M | $ 25.31 | -6.05 % | $ 1.71 B | USA |
 |
Retractable Technologies
RVP
|
12.8 M | $ 0.66 | -0.05 % | $ 19.8 M | USA |
 |
Pro-Dex
PDEX
|
4.84 M | $ 66.74 | -0.39 % | $ 219 M | USA |
 |
Predictive Oncology
POAI
|
25.9 M | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
45.5 M | $ 26.73 | -1.33 % | $ 1.28 B | USA |
 |
Stereotaxis
STXS
|
17.8 M | $ 1.79 | -4.53 % | $ 163 M | USA |
 |
Baxter International
BAX
|
2.89 B | $ 19.51 | 0.8 % | $ 10 B | USA |
 |
ResMed
RMD
|
739 M | $ 195.75 | 0.74 % | $ 28.6 B | USA |
 |
AtriCure
ATRC
|
311 M | $ 27.18 | -0.33 % | $ 1.3 B | USA |
 |
Harvard Bioscience
HBIO
|
17.7 M | $ 6.16 | -5.02 % | $ 273 M | USA |
 |
NeuroMetrix
NURO
|
6.33 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
42.1 M | $ 12.26 | 1.91 % | $ 501 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.28 B | $ 152.67 | 2.08 % | $ 43.9 B | USA |
 |
Nephros
NEPH
|
9 M | $ 3.44 | -4.32 % | $ 36.5 M | USA |
 |
OraSure Technologies
OSUR
|
47.7 M | $ 4.04 | -3.12 % | $ 297 M | USA |
 |
Repligen Corporation
RGEN
|
291 M | $ 122.49 | -3.21 % | $ 6.89 M | USA |